Innovations and Challenges in Renal Cancer
First Cambridge Conference - March 2004
This multidisciplinary educational forum was directed by
Michael B. Atkins, MD, to address critical issues in the field and develop an educational proceedings summarizing recent progress and outlining priorities for research and clinical care.
The proceedings of the meeting were published as a peer-reviewed supplement to the journal Clinical Cancer Research (Clinical Cancer Research Vol 10. No 18 (Part 2). Sept 15 2004.
The program was designed to review important aspects of renal cancer genetics biology, especially as they relate to early detection and therapy; discuss recent advances in prognostic classification of renal cancer, especially as these might relate to treatment selection; assess the roles of local therapy, immunotherapy, antiangiogenic therapy and molecularly-targeted agents in the current treatment of renal cancer; and assess recent advances in supportive care.
Educational Grant Support
Supported by educational grants from Schering Plough Corporation, Chiron Corporation, Genentech BioOncology, Novartis Pharmaceutical Corporation, Wyeth Pharmaceuticals, Bayer Pharmaceuticals, Celgene, Kidney Cancer Association and VHL Family Alliance.
Sponsorship
CME sponsorship was provided by InforMEDical Communications, Inc.
